Advaxis (ADXS) AI Stock Analysis

• Market Cap: $1.48M
• Dividend Yield: N/A
• Average Volume (3M): 287.00
• Price to Earnings (P/E): ―
• Beta (1Y): -2.25
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 42,633,400
• 10 Day Avg. Volume: 158
• 30 Day Avg. Volume: 287
• PEG Ratio: N/A
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.05
• Enterprise Value/Market Cap: 3.32
• Enterprise Value/Revenue: 3.43
• Enterprise Value/Gross Profit: -0.69
• Enterprise Value/Ebitda: -0.03
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 20 Underperform
• Price Target: ―

Advaxis faces substantial financial and operational challenges. The severe decline in revenues and persistent losses, coupled with technical indicators pointing to further downside risk, contribute to a low overall score. Valuation metrics are unhelpful due to negative earnings, and the drastic stock price drop post-earnings suggests investor pessimism.

Advaxis Business Overview & Revenue Model

Company Description

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

How the Company Makes Money

Advaxis primarily generates revenue through collaborative research and development agreements, as well as licensing deals with other biotechnology and pharmaceutical companies. These collaborations often involve upfront payments, milestone payments, and potential royalties on sales if the partnered products reach commercialization. Another potential revenue stream includes government grants or funding that support research and development activities. Significant partnerships and collaborations with industry players also contribute to its financial prospects by providing resources and shared expertise to advance its pipeline.

Advaxis Financial Statement Overview

Summary

Advaxis is experiencing severe financial challenges, with a dramatic decline in revenues, persistent losses, and a troubled balance sheet. The negative equity and cash flow deficits signal significant financial distress.

Income Statement

Advaxis has faced significant challenges on its income statement, with total revenue declining dramatically from $20.88 million in 2019 to just $13,000 in 2023. The company has consistently reported negative EBIT and net income, indicating persistent operational losses. The net profit margin is severely negative, highlighting profitability issues. The revenue growth rate has also been negative, reflecting a downward trend in sales.

Balance Sheet

The balance sheet indicates financial distress, with stockholders' equity turning negative by 2023, reflecting a substantial erosion of capital. The debt-to-equity ratio is not applicable due to negative equity, but total liabilities exceed total assets, indicating insolvency. Return on equity is deeply negative, further demonstrating financial instability.

Cash Flow

The cash flow statement reveals negative operating cash flow across all periods, with substantial free cash flow deficits indicating cash burn. However, recent financing activities have provided some liquidity, as reflected in the positive financing cash flow. The ratios of operating and free cash flow to net income are negative, highlighting cash flow challenges.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	13.00K	250.00K	3.24M	253.00K	2.33M
Gross Profit	0.00	-64.00K	-468.00K	-1.03M	1.05M
EBITDA	-35.87M	-15.78M	-18.77M	-24.39M	-17.56M
Net Income	-48.07M	-14.36M	-17.86M	-26.47M	-17.79M
Balance Sheet
Total Assets	16.58M	25.93M	46.78M	38.53M	20.05M
Cash, Cash Equivalents and Short-Term Investments	4.88M	25.21M	41.61M	25.18M	16.73M
Total Debt	8.32M	12.00K	40.00K	6.02M	299.00K
Total Liabilities	41.00M	2.30M	7.89M	8.35M	5.60M
Stockholders Equity	-24.42M	23.63M	38.89M	30.18M	14.45M
Cash Flow
Free Cash Flow	-29.48M	-15.48M	-15.90M	-22.69M	-16.28M
Operating Cash Flow	-29.48M	-15.28M	-15.44M	-21.94M	-14.95M
Investing Cash Flow	5.95M	-166.00K	-11.00K	-748.00K	-1.58M
Financing Cash Flow	26.00M	-956.00K	31.89M	15.50M	7.08M

Advaxis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADXS, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.03 is Neutral, neither overbought nor oversold. The STOCH value of -4.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADXS.

Advaxis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
GRI	45 Neutral	$4.92M	―	-468.00%	―	―	98.55%
SLRX	30 Underperform	$1.60M	―	-300.16%	―	―	79.57%
ZVSA	29 Underperform	$1.90M	―	-91.39%	―	―	99.39%
PCSA	29 Underperform	$6.58M	―	-192.72%	―	―	56.26%
PTIX	27 Underperform	$2.81M	―	-512.79%	―	―	-40.51%
ADXS	20 Underperform	$1.48M	―	197.20%	―	―	―